ATM and prostate cancer: We observed a higher proportion of men with aggressive prostate cancer carrying pathogenic variants in ATM than that in men with non-aggressive prostate cancer (14/787 carriers, 0.02% and 5/769 carriers, 0.01%, respectively), although the difference did not reach statistical significance (p = 0.06) [17].